Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Ana Carolina Caballero Gonzalez, Laura Escribà-Garcia, Cristina Ujaldón-Miró, Paula Pujol Fernández, Rosanna Montserrat-Torres, Eva Escudero-López, Irene García-Cadenas, Albert Esquirol, Maria Guardiola-Perello, Paola Jara-Bustamante, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2024) 144 (Supplement 1): 920.

https://doi.org/10.1182/blood-2024-210129

Published: 2024

Journal Articles

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Blood (2024) 144 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2024-203251

Published: 2024

Journal Articles

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Yadith Karina Lopez-Garcia, Sara Redondo Velao, Andres Gomez-De Leon, Irene García-Cadenas, Héctor Alejandro Vaquera Alfaro, Perla R. Colunga-Pedraza, Albert Esquirol, César Homero Gutierrez-Aguirre, José Carlos Jaime-Pérez, Jorge Sierra, Olga Cantu, Javier Briones, David Gomez-Almaguer, Rodrigo Martino

Blood (2024) 144 (Supplement 1): 4898.

https://doi.org/10.1182/blood-2024-210332

Published: 2024

Journal Articles

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Blood (2024) 144 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2024-204722

Published: 2024

Journal Articles

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Blood (2024) 144 (Supplement 1): 962.

https://doi.org/10.1182/blood-2024-205124

Published: 2024

Journal Articles

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Blood (2024) 144 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2024-207954

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Blood (2023) 142 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2023-174115

Published: 2023

Journal Articles

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Blood (2022) 140 (Supplement 1): 7754–7756.

https://doi.org/10.1182/blood-2022-164561

Published: 2022

Journal Articles

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Blood (2022) 140 (Supplement 1): 7631–7633.

https://doi.org/10.1182/blood-2022-167747

Published: 2022

Journal Articles

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Ana Carolina Carolina Caballero Gonzalez, Laura Escribà-García, Rosanna Montserrat, Eva Escudero-López, Paula Pujol-Fernández, Cristina Ujaldón-Miró, Irene García-Cadenas, Albert Esquirol, Rodrigo Martino, Jorge Sierra, Carmen Alvarez-Fernández, Javier Briones

Blood (2022) 140 (Supplement 1): 405–407.

https://doi.org/10.1182/blood-2022-167504

Published: 2022

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Blood (2021) 138 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2021-150992

Published: 2021

Journal Articles

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Josep-Maria Ribera, Mireia Morgades, Juana Ciudad, Pau Montesinos, Jordi Esteve, Eulàlia Genescà, Pere Barba, Jordi Ribera, Irene García-Cadenas, María José Moreno, Daniel Martínez-Carballeira, Anna Torrent, Pilar Martínez-Sánchez, Silvia Monsalvo, Cristina Gil, Mar Tormo, María Teresa Artola, Marta Cervera, José González-Campos, Carlos Rodríguez, Arancha Bermúdez, Andrés Novo, Beatriz Soria, Rosa Coll, María-Luz Amigo, Aurelio López-Martínez, Rosa Fernández-Martín, Josefina Serrano, Santiago Mercadal, Antònia Cladera, Alberto Giménez-Conca, María-Jesús Peñarrubia, Eugènia Abella, Ferran Vall-llovera, Jesús-María Hernández-Rivas, Antoni Garcia-Guiñon, Juan-Miguel Bergua, Beatriz de Rueda, María-José Sánchez-Sánchez, Alfons Serrano, María Calbacho, Natalia Alonso, Jose-Ángel Méndez-Sánchez, Raimundo García-Boyero, Matxalen Olivares, Susana Barrena, Lurdes Zamora, Isabel Granada, Ludovic Lhermitte, Evarist Feliu, Alberto Orfao

Blood (2021) 137 (14): 1879–1894.

https://doi.org/10.1182/blood.2020007311

Published: 2021

Includes: Supplemental data

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Claudia Nunez-Torron, MD, Adolfo Saez, Berta Mercedes Michael Fernández, Irene Garcia-Garcia, Juan Marquet Palomanes, Miguel Piris-Villaespesa, MD, Jesus Villarrubia, PhD, Valentín Garcia-Gutiérrez, MD PhD, Gemma Moreno Jiménez, MD, Javier Lopez Jimenez, MD PhD, Pilar Herrera Puente

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141907

Published: 2020

Journal Articles

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-137383

Published: 2020

Journal Articles

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-136627

Published: 2020

Journal Articles

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood (2019) 134 (Supplement_1): 5733.

https://doi.org/10.1182/blood-2019-126036

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Blood (2019) 134 (Supplement_1): 3325.

https://doi.org/10.1182/blood-2019-126507

Published: 2019

NARROW

HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30 + T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)

Efficacy and Safety of Reduced-Doses of Post-Transplant Cyclophosphamide in Matched Peripheral Blood Stem Cell Transplantation, a Multicenter Study

Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients: The Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30 + T-Cell Lymphoma: Clinical and Biological Studies

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Prognostic Impact of the Latency Time from the Administration of Cytotoxic Therapy to the Development of Therapy-Related Myeloid Neoplasms

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Clinical Validation of the Myelofibrosis Transplant Scoring System in an Independent Series of Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only